1129116

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549



FORM D

OMB APPROVAL

OMB Number:

3235-0076

Expires: December 31, 1993 Estimated average burden

hours per form 16.00

NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D SECTION 4(6), AND/OR UNIFORM LIMITED OFFERING EXEMPTION

SEC USE	ONLY
Prefix	Serial
DATE REC	EIVED

								
Name of Offering (check if this is an amendment an		dicate change.)						
Comr	non Stock and Warrants							
Filing Under (Check box(es) that apply): Rule 5	504	⊠Rule :	506 □Section 4	(6) DULOE				
Type of Filing:	New Filing		Amendment					
	A. BASIC IDENTIFICATION	N DATA						
1. Enter the information requested about the issuer								
Name of Issuer (Check if this is an amendment and	name has changed, and indic	ate change.)		,				
Control of the contro	and the second of the second o		* .	* / / · · · · · · · · · · · · · · · · ·				
Address of Executive Offices (Num	her and Street City State 7	n Code) T	elephone Number (Inc	luding Area Code)				
1735 North First Street, Ste. 309, San Jose, CA 9511	per and succe, Chy, plate, 24	p. Code)	707) 747-3001	iuding Mica Code)				
- Address of Principal Business Operations (Number, S		same as 🛶 🖛 T	elephone Number (Inc	luding Area Code)				
above profit to the best of the second	gradien de dage en en e	ARAP	PROPERTY OF THE PROPERTY OF TH					
gradient of the state of the st	$\mathcal{G}_{\mathcal{G}} = \{ \{ \mathbf{f} \in \mathcal{F} \mid \mathbf{f} \in \mathcal{F} \mid \mathbf{f} \in \mathcal{F} \} \} $	PROC	、こうり とし	4 4 4				
Brief Description of Business		¥						
Development of research, diagnostic and therapeut	ic products	ก คร	0 2003					
Type of Business Organization		۔ امال	<u> 17 7 000</u>					
그 선생님 그 생생님 그들이 있는 것이 되었다.	ited partnership, already for	med THG	other (please s	snecify)				
SNAME IEM								
			······································	·				
$\mathcal{L}(\mathcal{M}_{\mathcal{A}}}}}}}}}}$	Month Month	<u>Year</u>						
Actual or Estimated Date of Incorporation or Organiz	zation: April	97		Estimated				
Jurisdiction of Incorporation or Organization: (Enter	two-letter U.S. Postal Service	ce abbreviation fo	or State:	DE				
•	or Canada, FN for other forci			→				
		 						

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C 77d(6).

When to File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE a that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

- 2. Enter the information requested for the following:
 - Each promoter of the issuer, if the issuer has been organized within the past five years;
 - Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer:
 - Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and

Each general and managing partner of partnership issuers. Promoter ☐Beneficial Owner Check Box(es) Executive Officer General and/or Managing Partner that Apply: Director Full Name (Last name first, if individual) Walzer, Roy Business or Residence Address (Number and Street, City, State, Zip Code) 10 South Street, Litchfield, CT 06759 Check Box(es) Promoter Beneficial Owner ☐Executive Officer that Apply: **⊠**Director General and/or Managing Partner Full Name (Last name first, if individual) Neil, Garry Business or Residence Address (Number and Street, City, State, Zip Code) 536 G Stone Road, Benicia, CA 94510 Check Box(es) Promoter ⊠Beneficial Owner Executive Officer that Apply: □ Director
 General and/or Managing Partner Full Name (Last name first, if individual) Urnovitz, Howard Business or Residence Address (Number and Street, City, State, Zip Code) 783-22nd Avenue, San Francisco, CA 94121 Check Box(es) Promoter Beneficial Owner that Apply: General and/or Managing Partner Full Name (Last name first, if individual) Boeger, William Business or Residence Address (Number and Street, City, State, Zip Code) 409 Fairway Road, Sun Valley, ID 83353 Check Box(es) Promoter ⊠Beneficial Owner Executive Officer that Apply: Director General and/or Managing Partner Full Name (Last name first, if individual) Litchfield Fartners I, LP Business or Residence Address (Number and Street, City, State, Zip Code) 10 South Street, Litchfield, CT 06759 Check Box(es) Promoter ⊠Beneficial Owner Executive Officer General and/or Managing Partner that Apply: Director Full Name (Last name first, if individual) Pentagram Partners, L.P.

Business or Residence Address (Number and Street, City, State, Zip Code) 630 5th Avenue, 20th Floor, New York, NY 10111

,				В.	INFORMA	ΓΙΟΝ ABO	UT OFFER	ING			· · · · · · · · · · · · · · · · · · ·	
l. Has	the issuer s	old, or doe					ivestors in t 2, if filing u	_		Yes 🗌	No 🛭	
2. What	t is the min	imum inve	stment that	will be acc	epted from	any individ	ual?	•••••••••		\$		
3. Does	the offerin	g permit jo	oint ownersh	nip of a sing	gle unit?	***************************************	**************	•••••	******	Yes 🗌	No 🏻	
remu perso	neration for on or agent (5) persons	r solicitatio of a broker	n of purcha or dealer re	sers in con gistered wit	nection with th the SEC a	sales of se and/or with	paid or give courities in t a state or sta aler, you ma	he offering. ates, list the	If a perso	n to be liste e broker or	ed is an ass dealer. If n	ociated nore than
	•											
Full Nan	ne (Last nar	ne first, if	individual)	<u> </u>								
D	Did	A J 1	(N)	- 1 St+ C	Stee Ctate 7	: O-1-\						
Business	or Kesigen	ce Address	(Number a	na street, C	ity, State, 2	ip Code)			*			
Name of	Associated	Broker or l	Dealer						 	······		
States in	Which Per	son Listed	Has Solicite	ed or Intend	ls to Solicit	Purchasers	•	······································				
· · ·			ndividual St	-							_	
[AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
[IL] [MT]	[IN] [NE]	[IA] [NV]	[KS] [NH]	[KY] [NJ]	[LA] [NM]	[ME] [NY]	[MD] [NC]	[MA] [ND]	[MI] [OH]	[MN] [OK]	[MS] [OR]	[MO] [PA]
[RI]	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[VA]	[WV]	[WA]	[WY]	[PR]
	ne (Last nar			L		<u> </u>						
1 411 1 1411	io (Dust Hui	ac 11.51, 11	mar radar,								•	
Business	or Residen	ce Address	(Number a	nd Street, C	city, State, Z	ip Code)		·······				
Name of	Associated	Broker or l	Dealer									
States in	Which Per	son Listed	Has Solicite	ed or Intend	ls to Solicit	Purchasers						
(Check "	'All States"	or check i	ndividual S	tates)		•••••				All State	s 🗌	
[AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[MT]	[NE]	[NV]	[NH]	[NI]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]
[RI]	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[VA]	[WV]	[WI]	[WY]	[PR]
Full Nan	ne (Last nai	ne first, if	individual)									
Business	or Residen	ce Address	(Number a	nd Street, C	City, State, Z	ip Code)			 			
Name of	Associated	Broker or	Dealer					<u></u>				
States in	Which Per	son Listed	Has Solicite	ed or Intend	ls to Solicit	Purchasers			· · · · · · · · · · · · · · · · · · ·			
			ndividual S					· · · · · · · · · · · · · · · · · · ·	***************	All State	es 🗌	
[AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
[肛]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]
[RI]	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[VA]	[WV]	[WI]	[WY]	[PR]

	C. OFFERING PRICE, NUMBER OF INVESTORS, EXPE	NSES AND USE OF PROCE	EDS
1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box \(\square\) and indicate in the columns below the amounts of the securities offering for exchange and already exchanged.		
	Type of Security Debt	Aggregate Offering Price	Amount Already Sold
	Equity	\$500,000*	\$ 500,000*
	⊠ Common ☐ Preferred	<u> </u>	<u> </u>
٠	Convertible Securities (including warrants)	\$24,000*	\$24,000*
	Partnership Interests	\$ <u>24,300</u> \$	\$0-
	Other (Specify)		·
		\$	\$
	Total	\$524,000*	\$ <u>524,000*</u>
. ~	Answer also in Appendix, Column 3, if filing under ULOE.		
	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."	•	
		Number Investors	Aggregate Dollar Amoun of Purchases
	Accredited Investors	1 tumber investors	\$_ 524,000
	Non-accredited Investors		\$
	Total (for filings under Rule 504 only)	-0-	
	· · · · · · · · · · · · · · · · · · ·		\$ <u>-0-</u>
	Answer also in Appendix, Column 4, if filing under ULOE.		
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1.		
	Type of Offering	Type of Security	Dollar Amount Sold
	Rule 505		\$
	Regulation A		\$
	Rule 504		\$
	Total		\$
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees		\$
	Printing and Engraving Costs	· 🗖	\$
	Legal Fees	\boxtimes	\$
	Accounting Fees	$\overline{\Box}$	\$
	Engineering Fees	· H	\$
	Sales Commissions (specify finders' fees separately)	ī	\$
	Other Expenses (Identify)		\$
	Total	$\overline{\boxtimes}$	\$2,000
	b. Enter the difference between the aggregate offering price given in response to Part C - Question 1 and total expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross proceeds to the issuer"		\$ 522,000*

C. OFFERING PRICE, NUMBER OF INVEST	ORS, EXPENSES AND USE OF PROC	EEDS
5. Indicate below the amount of the adjusted gross proceeds to the issue proposed to be used for each of the purposes shown. If the amount for purpose is not known, furnish an estimate and check the box to the leastimate. The total of the payments listed must equal the adjusted groceeds to the issuer set forth in response to Part C - Question 4.b a	or any eft of the ross bove.	
	Payment to Officers, Directors, & Affiliates	
Salaries and fees		Payment To Others \$ \$ \$ \$
this offering that may be used in exchange for the assets or securities of issuer pursuant to a merger)	\$	\$
Repayment of indebtedness Working capital		□ \$ ⋈ \$ <u>522,000</u>
Other (specify): Column Totals		□ \$ ⋈ \$ <u>522,000</u>
Total Payments Listed (column totals added)		<u>522,000</u>
D. FEDERALS	SIGNATURE	
The issuer had duly caused this notice to be signed by the undersigned of following signature constitutes an undertaking by the issuer to furnish to request of its staff, the information furnished by the issuer to any non-account of the information furnished by the issuer to any non-account of the information furnished by the issuer to any non-account of the information furnished by the issuer to any non-account of the information furnished by the issuer to any non-account of the information furnished by the issuer to any non-account of the information furnished by the issuer to any non-account of the information furnished by the issuer to any non-account of the information furnished by the issuer to any non-account of the information furnished by the issuer to any non-account of the information furnished by the issuer to any non-account of the information furnished by the issuer to any non-account of the information furnished by the issuer to any non-account of the information furnished by the issuer to any non-account of the information furnished by the issuer to any non-account of the information furnished by the issuer to any non-account of the information furnished by the issuer to any non-account of the information furnished by the information furnished by the information of the informa	o the U.S. Securities and Exchange Co	ommission, upon written
following signature constitutes an undertaking by the issuer to furnish to request of its staff, the information furnished by the issuer to any non-activation (Print or Type)	o the U.S. Securities and Exchange Co	ommission, upon written
following signature constitutes an undertaking by the issuer to furnish to request of its staff, the information furnished by the issuer to any non-active constitution of the issuer to furnish the issuer to furnish the issuer to any non-active constitution of the issuer to active constitution of the issuer to activ	o the U.S. Securities and Exchange Coccedited investor pursuant to paragrap Signature	ommission, upon written th (b)(2) of Rule 502.
following signature constitutes an undertaking by the issuer to furnish to request of its staff, the information furnished by the issuer to any non-activate (Print or Type) Chronix Biomedical, Inc. Name of Signer (Print or Type)	o the U.S. Securities and Exchange Cocredited investor pursuant to paragraph Signature Title of Signer (Print or Type)	ommission, upon written h (b)(2) of Rule 502.
following signature constitutes an undertaking by the issuer to furnish to request of its staff, the information furnished by the issuer to any non-activate (Print or Type) Chronix Biomedical, Inc. Name of Signer (Print or Type)	o the U.S. Securities and Exchange Cocredited investor pursuant to paragraph Signature Title of Signer (Print or Type)	ommission, upon written th (b)(2) of Rule 502.
following signature constitutes an undertaking by the issuer to furnish to request of its staff, the information furnished by the issuer to any non-activate (Print or Type) Chronix Biomedical, Inc. Name of Signer (Print or Type)	o the U.S. Securities and Exchange Cocredited investor pursuant to paragraph Signature Title of Signer (Print or Type)	ommission, upon written th (b)(2) of Rule 502.
following signature constitutes an undertaking by the issuer to furnish to request of its staff, the information furnished by the issuer to any non-activate (Print or Type) Chronix Biomedical, Inc. Name of Signer (Print or Type)	o the U.S. Securities and Exchange Cocredited investor pursuant to paragraph Signature Title of Signer (Print or Type)	ommission, upon written h (b)(2) of Rule 502.
following signature constitutes an undertaking by the issuer to furnish to request of its staff, the information furnished by the issuer to any non-activate (Print or Type) Chronix Biomedical, Inc. Name of Signer (Print or Type)	o the U.S. Securities and Exchange Cocredited investor pursuant to paragraph Signature Title of Signer (Print or Type)	ommission, upon written th (b)(2) of Rule 502.
following signature constitutes an undertaking by the issuer to furnish to request of its staff, the information furnished by the issuer to any non-activate (Print or Type) Chronix Biomedical, Inc. Name of Signer (Print or Type)	o the U.S. Securities and Exchange Cocredited investor pursuant to paragraph Signature Title of Signer (Print or Type)	ommission, upon written th (b)(2) of Rule 502.
following signature constitutes an undertaking by the issuer to furnish to request of its staff, the information furnished by the issuer to any non-activate (Print or Type) Chronix Biomedical, Inc. Name of Signer (Print or Type)	o the U.S. Securities and Exchange Cocredited investor pursuant to paragraph Signature Title of Signer (Print or Type)	ommission, upon written th (b)(2) of Rule 502.
following signature constitutes an undertaking by the issuer to furnish to request of its staff, the information furnished by the issuer to any non-activate (Print or Type) Chronix Biomedical, Inc. Name of Signer (Print or Type)	o the U.S. Securities and Exchange Cocredited investor pursuant to paragraph Signature Title of Signer (Print or Type)	ommission, upon written th (b)(2) of Rule 502.
following signature constitutes an undertaking by the issuer to furnish to request of its staff, the information furnished by the issuer to any non-activate (Print or Type) Chronix Biomedical, Inc. Name of Signer (Print or Type)	o the U.S. Securities and Exchange Cocredited investor pursuant to paragraph Signature Title of Signer (Print or Type)	ommission, upon written th (b)(2) of Rule 502.
following signature constitutes an undertaking by the issuer to furnish to request of its staff, the information furnished by the issuer to any non-activate (Print or Type) Chronix Biomedical, Inc. Name of Signer (Print or Type)	o the U.S. Securities and Exchange Cocredited investor pursuant to paragraph Signature Title of Signer (Print or Type)	ommission, upon written th (b)(2) of Rule 502.
following signature constitutes an undertaking by the issuer to furnish to request of its staff, the information furnished by the issuer to any non-activate (Print or Type) Chronix Biomedical, Inc. Name of Signer (Print or Type)	o the U.S. Securities and Exchange Cocredited investor pursuant to paragraph Signature Title of Signer (Print or Type)	ommission, upon written h (b)(2) of Rule 502.
following signature constitutes an undertaking by the issuer to furnish to request of its staff, the information furnished by the issuer to any non-activate (Print or Type) Chronix Biomedical, Inc. Name of Signer (Print or Type)	o the U.S. Securities and Exchange Corredited investor pursuant to paragrap Signature Title of Signer (Print or Type) President	mmission, upon written h (b)(2) of Rule 502. Date September 2003

E. STATE SIGNATURE

	provisions of such rule?		Yes 🗌 No 🛛
	See Appendix, Column	5, for state response.	4
2.	The undersigned issuer hereby undertakes to furnish to the state admit (17 CFR 239.500) at such times as required by state law.	nistrator of any state in which the notice	e is filed, a notice on Form D
3.	The undersigned issuer hereby undertakes to furnish to any state adrissuer to offerees.	ninistrators, upon written request, infor	mation furnished by the
4.	The undersigned issuer represents that the issuer is familiar with the limited Offering Exemption (ULOE) of the state in which this notice this exemption has the burden of establishing that these conditions limited the state in the state in which the state in which this notice this exemption has the burden of establishing that these conditions limited the state in the state in the state in which the state in which this notice this exemption has the burden of establishing that these conditions limited the state in the st	is filed and understands that the issuer	
	e issuer has read this notification and knows the contents to be true ardersigned duly authorized person.	nd has duly caused this notice to be sign	ned on its behalf by the
Iss	suer (Print or Type) Chronix Biomedical, Inc.	Signature /	Date September 20, 2003
Na	une of Signer (Print or Type) William A. Boeger	Title of Signer (Print or Type) President	

Instruction:

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D

must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

4 Disqualification under State ULOE (if yes, attach explanation of Type of security and aggregate offering price offered in State waiver granted Intend to sell to non-accredited Type of investor and amount purchased in State investors in State (Part B-Item (Part C-Item 1) (Part C-Item 2) (Part E-Item 1) 1) Numb Number of er of Accredited Common Stock Non-State Yes No and Warrants Investors Yes No Amount Accre Amount dited Invest ors ALΑK ΑZ AR CA CO CTDE DC FL GA Н ID L \mathbf{N} IA KS KY LA ME MD MA М MN

MS		ч					ļ	-	-
MO				<u> </u>					<u> </u>
MT	 							<u> </u>	
NE					·	 -		 	
NV									
NH .									<u> </u>
NJ									
NM					`				}
NY		X	\$524,000	1	\$524,000	0			X
NC									
ND									
OH									
OK					,				
OR.		-							
PA									
RI					·				
SC									
SD									
TN									
TX		-							
UT					·				
VI									
VA									
WA							,		
WV									
WI									
WY									
PR	·								

ANNEX C.1

This Form D relates to (i) the sale and issuance of Common Stock and Warrants and (ii) the sale and issuance of Common Stock upon exercise of the Warrants. The amount reported under "Convertible Securities" is the exercise price of the Warrants. The "Adjusted Gross Proceeds" in Section C.4.b. and "Total Payments" in Section C.5. assumes that all the Warrants have been exercised.